Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Figure Technology Solutions Reports Preliminary Q4 2025 & December Operating Data
-
Dan Bongino Returns To the Cumulus Podcast Network With the Relaunch of The Dan Bongino Show
-
iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference
-
AGM Holdings Signs Strategic Memorandum of Understanding to Enter the New Arena of Real-World Asset (RWA) Tokenization
-
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
-
3 E Network Announces the Signing of Land Lease Agreement with City of Mikkeli, Finland
-
Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2026 Milestones
-
FTI Consulting Expands Transactions Communications Capabilities with Two Senior Hires
-
EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance
-
Kiniksa Pharmaceuticals Provides Corporate Update
-
Dimensional Fund Advisors Ltd. : Form 8.3 - GREENCORE GROUP PLC - Ordinary Shares
-
Kitron ASA: Completion of acquisition of DeltaNordic and issuance of consideration shares
-
Delfin Midstream Extends Letter of Award with Samsung Heavy Industries and Executes Purchase Order with Siemens Energy
-
From Combat to Crisis Response: ParaZero's DropAir Achieves Major 2025 Milestones in Precision Airdrops Proven in Recent Conflicts
-
From Combat to Crisis Response: ParaZero's DropAir Achieves Major 2025 Milestones in Precision Airdrops Proven in Recent Conflicts
-
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
-
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
-
Kyivstar Launches 5G Pilot Program in Lviv
-
Dimensional Fund Advisors Ltd. : Form 8.3 - JUST GROUP PLC - Ordinary Shares
-
Invitation to HMS Networks’ fourth quarter conference call 2025
-
Kaldalón hf.: Routine Announcement Regarding Share Buybacks Pursuant to Buyback Program
-
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
-
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares
-
Pet Valu Appoints Carmen Fortino and Matt Reindel to Board of Directors
-
GoGuardian Launches Hall Pass for Safer Hallways, More Classroom Learning
-
Gaming and Leisure Properties, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call
-
NexGold Provides Summary of 2025 Activities and Key Priorities for 2026
-
Canada’s Biggest Popcorn Celebration: Cineplex Expands National Popcorn Day to Four Days
-
P10 Announces Upcoming Name Change
-
KEY Investment Partners Acquires BellRock Brands’ Portfolio, Home of Mary’s Medicinals, Dixie and Other Top Names
-
RAD Increases Ownership in Radiopharm Ventures to 87.5%
-
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
-
Lyra Therapeutics Provides Corporate Update
-
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
-
Stallion Uranium Refines Coyote Target with Highly Conductive Anomalies from Ground EM Survey, Mobilizes Stone Island VTEM Survey
-
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
-
First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025
-
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
-
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
-
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
-
Zumiez Inc. Reports Holiday 2025 Sales Results
-
Noodles & Company Announces Preliminary Revenue Results for the Fourth Quarter of 2025
-
Emerita Resources Provides Corporate Update
-
Skye Provides 2026 Corporate Outlook
-
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
-
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
-
Highwoods Announces Investment Activity
-
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
-
Sable Announces Director Change
